RxDoctor Payments Data

Vasudev Ananthram, MD

Cardiovascular Disease · Williamsburg, VANPI 1972570349

Payments from drug & device makers

$723in general payments, 2019–2025

Across 36 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$110
  • Philips North America LLC$95
  • Biotronik Inc.$89
  • Boehringer Ingelheim$71
  • Scpharmaceuticals Inc.$63
  • Amgen$61
  • plus $235 from 8 others

What the payments were for

  • Food & beverage$723100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$723 in reported general payments places this provider in the 30th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$346,596
Medicare patients
2,205
Services billed
7,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban685$855,630
XareltoRivaroxaban268$316,215
JardianceEmpagliflozin94$66,605
EntrestoSacubitril/Valsartan43$49,812
Repatha SureclickEvolocumab62$49,443
FarxigaDapagliflozin Propanediol15$25,386
Dofetilide92$14,443
Metoprolol Succinate789$13,138
VascepaIcosapent Ethyl12$11,374
Potassium Chloride288$8,687
Atorvastatin Calcium723$8,017
Praluent PenAlirocumab11$6,476
Valsartan170$5,574
Ezetimibe142$5,133
Losartan Potassium481$4,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$18$316,215268 claims
Boehringer IngelheimJardiance$71$66,60594 claims
NovartisEntresto$110$49,81243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Williamsburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →